Role of topoisomerase I inhibitors in small-cell lung cancer

ONCOLOGY

Volumn 15, Issue 7 SUPPL. 8, 2001, Pages 9-13

  Fukuoka, Masahiro ^a  

^a KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CAMPTOTHECIN; CISPLATIN; DNA TOPOISOMERASE; DRUG DERIVATIVE; ENZYME INHIBITOR; ETOPOSIDE; IRINOTECAN;

CLINICAL TRIAL; DRUG ANTAGONISM; HUMAN; LUNG TUMOR; REVIEW; SMALL CELL CARCINOMA; SURVIVAL;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; CARCINOMA, SMALL CELL; CISPLATIN; CLINICAL TRIALS; DNA TOPOISOMERASES, TYPE I; ENZYME INHIBITORS; ETOPOSIDE; HUMANS; LUNG NEOPLASMS; SURVIVAL ANALYSIS;

EID: 0035405025     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (4)

1. Kelly K: New chemotherapy agents for small-cell lung cancer. Chest 117:156-162, 2000.
2. Fukuoka, M, Furuse K, Saijo N, et al: Randomized trial of cyclophosphamide, doxorubicin, and vincristine versus cisplatin and etoposide versus alternation of these regimens in small-cell lung cancer. J Natl Cancer Inst 83:855-861, 1991.
3. Roth BJ, Johnson DH, Einhorn LH, et al: Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these regimens in extensive small-cell lung cancer: A phase III trial of Southeastern Cancer Study Group. J Clin Oncol 10:282-291, 1992.
4. Kunimoto T, Nitta K, Tanaka T, et al: Antitumor activity of 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxy-camptothecin, a novel water-soluble derivative of camptothecin, against murine tumors. Cancer Res 47:5944-5947, 1987.